Suggestions
Justin Eyquem
Assistant Professor UCSF | Gladstone and PICI Investigator | co-founder Mnemo Tx
Justin Eyquem is an Assistant Professor at the University of California, San Francisco (UCSF) specializing in cancer immunotherapy and gene editing technologies.1 His research focuses on developing next-generation cell therapies for cancer treatment.2
Expertise and Skills
Justin Eyquem's areas of expertise include:
- Adoptive Immunotherapy
- Chimeric Antigen Receptor (CAR) T-cell therapy
- Genome editing techniques, particularly CRISPR technology1
Professional Achievements
Research Recognition:: Eyquem was recently selected as one of the five Pew-Stewart Scholars, an honor bestowed upon promising early-career scientists in cancer research.3
Public Engagement:: He actively shares insights on next-generation cell therapies, participating in podcasts such as the Parker Institute for Cancer Immunotherapy's "From Bench to Fireside".2
Recent Activities
Justin Eyquem is involved in various research and outreach activities:
- He is working on improving the manufacturing and access of gene-edited primary immune cell therapies.4
- Eyquem participates in fundraising efforts for cancer research, such as the ACRF's 2km a Day in May challenge.3
It's worth noting that while some search results mention a position at the Karolinska Institute, the most recent and relevant information indicates that Justin Eyquem is currently an Assistant Professor at UCSF.1
Highlights
Truly honored to receive the Pew-Stewart scholarship! Thank you to The Pew Charitable Trusts and the selection committee for supporting my lab's efforts to develop transformative cancer treatments. I'm so excited to join the Pew community!
🚨 New study from the lab! We developed SEED selection, a method to purify KnockIns at multiple loci in a single step. Better, It takes no space in the donor template, can be easily multiplexed and its all through negative selection!
Using SEED, we fully reprogrammed three critical loci encoding T cell specificity, co-receptor expression, and MHC expression with up to 90% purity after one negative selection step for six simultaneous edits (three knock-ins and three knockouts).
Congrats Chris Chang! and thank you to all the collaborators from the Brian Shy, Alex Marson labs.
